Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) EPS (Weighted Average and Diluted) (2019 - 2025)

ImmunityBio (IBRX) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$0.06 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 33.33% to -$0.06 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.38 through Dec 2025, up 39.68% year-over-year, with the annual reading at -$0.38 for FY2025, 38.71% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.06 at ImmunityBio, up from -$0.07 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was -$0.06 in Q4 2025, with the low at -$0.38 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.21, with a median of -$0.22 recorded in 2021.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 40.74% in 2023, then skyrocketed 76.32% in 2024.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.23 in 2021, then dropped by 17.39% to -$0.27 in 2022, then crashed by 40.74% to -$0.38 in 2023, then surged by 76.32% to -$0.09 in 2024, then soared by 33.33% to -$0.06 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.06, -$0.07, and -$0.1 for Q4 2025, Q3 2025, and Q2 2025 respectively.